Sign In
Buy ENTA
$13.37
+0.710 (+5.61%)
At Close: Jun 22, 2026
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
04:01pm, Monday, 09'th Feb 2026
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological
KalVista Pharmaceuticals (NASDAQ:KALV) vs. Enanta Pharmaceuticals (NASDAQ:ENTA) Financial Review
01:34am, Thursday, 05'th Feb 2026
KalVista Pharmaceuticals (NASDAQ: KALV - Get Free Report) and Enanta Pharmaceuticals (NASDAQ: ENTA - Get Free Report) are both small-cap medical companies, but which is the better business? We will co
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of “Moderate Buy” by Brokerages
01:41am, Sunday, 18'th Jan 2026
Shares of Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven research firms that are covering the firm, MarketBeat
Enanta Pharmaceuticals, Inc. (ENTA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
08:25pm, Wednesday, 14'th Jan 2026
Enanta Pharmaceuticals, Inc. (ENTA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook
07:00am, Thursday, 08'th Jan 2026
WATERTOWN, Mass.--(BUSINESS WIRE)-- #KIT--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunol
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
07:00am, Monday, 05'th Jan 2026
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for vir
Enanta Pharmaceuticals (ENTA) Surges 5.9%: Is This an Indication of Further Gains?
10:21am, Monday, 22'nd Dec 2025
Enanta Pharmaceuticals (ENTA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price
Wall Street Analysts Believe Enanta Pharmaceuticals (ENTA) Could Rally 44.85%: Here's is How to Trade
10:56am, Friday, 21'st Nov 2025
The consensus price target hints at a 44.9% upside potential for Enanta Pharmaceuticals (ENTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ear
Enanta: Maintaining Buy Rating Based On Zelicapavir Potential In RSV Development
03:01pm, Wednesday, 19'th Nov 2025
Enanta Pharmaceuticals (ENTA) remains a "Buy" due to promising secondary endpoints for zelicapavir in RSV, despite missing its primary endpoint. Company's pipeline strength is supported by EDP-323's p
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025
04:01pm, Monday, 17'th Nov 2025
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
07:00am, Tuesday, 04'th Nov 2025
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunol
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunol
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunol
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological
U.S. stock futures were lower this morning, with the Dow futures falling more than 200 points on Wednesday.
